The prevalence of thromboembolic events among COVID-19 patients admitted to a single centre intensive care unit (ICU): an epidemiological study from a Malaysian population by Nur Farhani Mansor, Izzati Abdul Halim Zaki, Lee Chew Kiok, Eng Kar Seng, Tharmini Ravi, Mohan Pathmanathan, Khang Wen Goh, Long Chiau Ming, Pakhrur Razi, Hanis Hanum Zulkifly

“…TE event is a combination of venous [(deep vein thrombosis (DVT), pulmonary embolism (PE)] and arterial (myocardial infarction (MI), stroke) thromboembolism.Results Mean (SD) age 56.6 (13.7), 63.5% were male, 61.6% Malays, median (IQR) 7 (3–14) days of ICU stay, 64.2%, 53.2% and 20.9% had underlying hypertension, diabetes and obesity respectively. …”
Get full text

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme by Peter Nash, Yoshiya Tanaka, Kevin L Winthrop, Eun Bong Lee, Xavier Mariette, Jeffrey R Curtis, Kenneth Kwok, Connie Chen, Pinaki Biswas, Lisy Wang, Christina Charles-Schoeman, Ann Madsen, Stanley B Cohen, Andrea Shapiro, Jürgen Wollenhaupt

“…IRs (95% CI) for gastrointestinal perforations, deep vein thrombosis, pulmonary embolism, venous thromboembolism, arterial thromboembolism and major adverse cardiovascular events were 0.1 (0.1 to 0.2), 0.2 (0.1 to 0.2), 0.1 (0.1 to 0.2), 0.3 (0.2 to 0.3), 0.4 (0.3 to 0.5) and 0.4 (0.3 to 0.5), respectively. …”
Get full text

Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events by Mark Lebwohl, Atul Deodhar, Sergio Schwartzman, Carlo Salvarani, Meghan Feely McDonald, Natalia Bello, Elsie L. Grace, Elsa Inman, Andris Kronbergs, Marcus Ngantcha, Proton Rahman, Kim A. Papp, Joseph F. Merola, Alice B. Gottlieb, Andrew Blauvelt

“…Abstract Introduction Psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) may confer an increased risk for cardiovascular (CV) disease, including major adverse cerebro-cardiovascular events (MACE), deep vein thrombosis (DVT), and pulmonary embolism (PE). Patients with these conditions are often exposed for extended time periods to biologics, such as ixekizumab (IXE). …”
Get full text

Weight-based enoxaparin thromboprophylaxis in young trauma patients: analysis of the CLOTT-1 registry by Sarah Lombardo, Ram Nirula, Elliott R Haut, Scott Brakenridge, Brandon Bruns, Charles E Wade, M Margaret Knudson, Thomas Scalea, Todd W Costantini, Lisa Marie Knowlton, David Spain, Ernest E Moore, Michelle K McNutt, Matthew J Martin, Andrew J Kerwin, George C Velmahos, Bruce Crookes, Marta McCrum, Lucy Kornblith, Mark D Cipolle, Laszlo N Kiraly, David J Milia, Alicia Mohr, Frederick Rogers, Sherry Sixta, Jade Nunez

“…Early prophylaxis was associated with lower VTE rate (1.4% vs. 5.0%; p=0.001) and deep vein thrombosis (0.9% vs. 4.4%; p<0.001), but not pulmonary embolism (0.7% vs. 1.4%; p=0.259). After adjustment, VTE incidence did not differ by dosing strategy (adjusted OR (aOR) 0.75, 95% CI 0.38 to 1.48); however, early administration was associated with a significant reduction in VTE (aOR 0.47, 95% CI 0.30 to 0.74).Conclusion In young trauma patients, WB prophylaxis is not associated with reduced VTE rate when compared with SFD. …”
Get full text

Genetic evidence for the causal effects of air pollution on the risk of respiratory diseases by Yanjuan Wu, Yuting Zhang, Jingcun Wang, Qiming Gan, Xiaofen Su, Sun Zhang, Yutong Ding, Xinyan Yang, Nuofu Zhang, Kang Wu

“…Results: TSMR analysis revealed that exposure to PM2.5 increased the risk of early-onset chronic obstructive pulmonary disease (COPD), pneumonia, pulmonary embolism and lung cancer. PM2.5–10 exposure was associated with an increased risk of lung cancer, while PM10 exposure increased the risk of pneumonia and bronchiectasis. …”
Get full text